Early Metabolic Response in Locally Advanced Esophageal Cancer Undergoing Induction Chemoradiotherapy

Universitaire Ziekenhuizen KU Leuven

Overview

Early metabolic response evaluation may predict clinical and histopathological response after neoadjuvant chemotherapy. Its value in neoadjuvant chemoradiotherapy (CRT) is unknown. Our aim was to assess the value of early metabolic response after one cycle of chemotherapy using 18-FDG-PET-CT to predict pathological response and outcome in cT2-4 N0/+ esophageal cancer treated by neoadjuvant CRT and esophagectomy.

Study Type

OBSERVATIONAL

Conditions

Esophageal Carcinoma (Squamous Cell Carcinoma - Adenocarcinoma)

Interventions

18-FDG-PET-CTOTHER

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * locally advanced esophageal cancer (cT2-4 N0/+) Exclusion Criteria: * PET-CT not performed at UZLeuven * Other tumor types * Distant metastases (organ)

Locations (1)

UZLeuven

Leuven, Vlaams-Brabant, Belgium

Outcomes

Primary Outcomes

early metabolic response to predict pathological response and outcome

assess the value of early metabolic response with 18-FDG-PET-CT (i.e. a decrease of ≥ 35% of SUVmean) after a single cycle of chemotherapy followed by neoadjuvant CRT and esophagectomy as a tool to predict pathological response and outcome in patients with cT2-4N0/+ carcinoma of the esophagus and GE-junction (GEJ).

Secondary Outcomes

to study correlations between early metabolic response, late metabolic response, histopathological response and outcome.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.